Skip to main content
Back
Watch Compare

Vanda Pharmaceuticals Inc.

Data quality: 100%
VNDA
Nasdaq Manufacturing Chemicals
$7.22
▼ $0.11 (-1.50%)
Mkt Cap: 430.01 M
Price
$7.28
Mkt Cap
430.01 M
Day Range
—
52-Week Range
—
Volume
—
Open —
50D / 200D Avg
—
50D / 200D Avg
—

Quick Summary

Key Takeaways

Revenue declined -5.30% annually over 5 years
Negative free cash flow of -110.44 M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 14.02%
Capital efficient — spends only 0.46% of revenue on capex

Growth

Revenue Growth (5Y)
-5.30%
Below sector avg (1.82%)
Revenue (1Y)8.72%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-46.30%
Above sector avg (-53.34%)
ROIC-24.21%
Net Margin-102.02%
Op. Margin-69.95%

Safety

Debt / Equity
N/A
Current Ratio3.12
Interest CoverageN/A

Valuation

PE (TTM)
-1.95
Below sector avg (-1.47)
P/B Ratio0.92
EV/EBITDAN/A
Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (1364 peers)
Metric Stock Sector Median
P/E -2.0 -1.5
P/B 0.9 1.6
ROE % -46.3 -53.3
Net Margin % -102.0 -41.5
Rev Growth 5Y % -5.3 1.8
D/E — 0.3

Analyst Price Target

5 analysts
Buy
Current
$7.22
+114.7%
Target
$15.50
$7.50
$17.00
$24.00
Forecast
Forward EPS -$0.79
Est. Revenue 353.27 M

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2027 -$0.79
-$1.23 – -$0.43
 353.27 M 5
FY2026 -$2.24
-$2.79 – -$1.65
 257.11 M 5

Earnings Surprises

Last 4 quarters
Quarter Est. EPS Actual EPS Surprise
Q42025 -$1.33 -$2.39 -80.4%
Q32025 -$0.45 -$0.38 +16.2%
Q22025 -$0.36 -$0.46 -29.0%
Q12025 -$0.60 -$0.50 +16.2%

ETFs Holding This Stock

MEDX logo MEDX Horizon Kinetics Medical ETF
0.72% weight
BRSIX BRSIX
0.37% weight
QASCX QASCX
0.19% weight
QLSCX QLSCX
0.19% weight
QCSCX QCSCX
0.19% weight
BDSCX BDSCX
0.12% weight
BDSKX BDSKX
0.12% weight
BDSIX BDSIX
0.12% weight
BDSAX BDSAX
0.12% weight
PSGIX PSGIX
0.12% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) 8.72% Revenue Growth (3Y) 5.92%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -5.30% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 216.11 M Net Income (TTM) -220.47 M
ROE -46.30% ROA -35.97%
Gross Margin N/A Operating Margin -69.95%
Net Margin -102.02% Free Cash Flow (TTM) -110.44 M
ROIC -24.21% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 3.12
Interest Coverage N/A Asset Turnover 0.35
Working Capital 249.63 M Tangible Book Value 357.16 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -1.95 Forward P/E N/A
P/B Ratio 0.92 P/S Ratio 1.99
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -25.68%
Market Cap 430.01 M Enterprise Value 359.99 M
Per Share
EPS (Diluted TTM) -3.74 Revenue / Share 3.66
FCF / Share -1.87 OCF / Share -1.85
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 0.46% FCF Conversion 50.09%
SBC-Adj. FCF -120.63 M Growth Momentum 14.02

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 216.11 M 198.77 M 192.64 M 254.38 M 268.68 M
Net Income -220.47 M -18.90 M 2.51 M 6.28 M 33.15 M
EPS (Diluted) -3.74 -0.33 0.04 0.11 0.58
Gross Profit — — — — —
Operating Income -151.17 M -40.66 M -13.95 M 6.33 M 42.17 M
EBITDA — — — — —
R&D Expenses 109.27 M 74.43 M 76.82 M 85.77 M 75.36 M
SG&A Expenses 237.95 M 146.41 M 112.88 M 136.49 M 124.05 M
D&A — — — — —
Interest Expense — — — — —
Income Tax 81.83 M -4.02 M 3.83 M 5.03 M 9.21 M

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 488.95 M 656.20 M 648.44 M 634.25 M 593.79 M
Total Liabilities 161.76 M 117.66 M 103.53 M 107.05 M 88.86 M
Shareholders' Equity 327.19 M 538.55 M 544.91 M 527.20 M 504.93 M
Total Debt — — — — —
Cash & Equivalents 84.85 M 102.32 M 135.82 M 135.03 M 52.07 M
Current Assets 347.26 M 438.89 M 432.95 M 519.29 M 478.30 M
Current Liabilities 145.16 M 99.98 M 87.70 M 91.44 M 74.42 M